HSP90AA1 and neoplasm: Additionally, synergistic drug combinations are aimed to maximize sensitivity over tumor cells while minimizing toxicity in normal cells, which has been a limiting factor for the use of HSP90 inhibitors in patients (Neckers & Workman, 2012).